Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279846 · ClinicalTrials.gov registry record · Phase 3
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
A Phase 3 study of Onychomycosis, sponsored by Moberg Pharma AB.
- Active
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT05279846 is a Phase 3 study of Onychomycosis that is active but no longer recruiting, run by Moberg Pharma AB. The registered enrollment target is 350 participants, above the 63-participant average among 11 other Onychomycosis trials with a reported enrollment target (456% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05279846, a Phase 3 study of Onychomycosis, is active but no longer recruiting, sponsored by Moberg Pharma AB.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)
Conditions Studied
Interventions
- DRUG MOB015B
- DRUG Vehicle (Placebo Comparator)
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- Center for Dermatology Clinical Research,Inc - Fremont
- Dermatology Research Associates - Los Angeles
- Center for Clinical Research - San Francisco
Florida
- Olympian Clinical Research - Clearwater
- Driven Research LLC - Coral Gables
- Doctors Research Institute Corporation - South Miami
Louisiana
- DelRicht Research - Baton Rouge - Baton Rouge
- IMA Clinical Research - Monroe
Michigan
- David Fivenson, MD, Dermatology, PLLC - Ann Arbor
- Michigan Center for Skin Care Research - Clinton Township
New York
- Forest Hills Dermatology Group - Kew Gardens
- Weill Cornell Medicine Dermatology - New York
Alabama
- University of Alabama Hospital - Birmingham
Colorado
- Colorado Medical Research Center - Denver
Illinois
- Podiatry 1st - O'Fallon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2025-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279846
The ClinicalTrials.gov registry entry for NCT05279846 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 11 other Onychomycosis trials with a reported enrollment target (456% higher). The listed sponsor is Moberg Pharma AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 2 interventions - of which MOB015B is the first listed.
NCT05279846 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05279846 about?
NCT05279846 is a clinical study titled "A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)". This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)
What is the current status of trial NCT05279846?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2022-05-09. Estimated completion is 2025-01.
What conditions does trial NCT05279846 study?
This clinical trial studies the following conditions: Onychomycosis.
What interventions are being tested in trial NCT05279846?
The interventions under investigation include: MOB015B (DRUG), Vehicle (Placebo Comparator) (DRUG).
Who is sponsoring clinical trial NCT05279846?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279846 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
COMPLETED · NA
-
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
COMPLETED · Phase 2
-
Spread of Dermatophytes Among Families
COMPLETED
-
Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
COMPLETED · NA
-
Diode Laser Treatment of Onychomycosis
COMPLETED · NA
-
Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.